ImmunityBio (IBRX) Extends Gains to 10th Day on 700% Anktiva Sales Jump; Time to Book Profits?

Core Insights - ImmunityBio Inc. (NASDAQ: IBRX) has experienced a significant increase in stock performance, with a 30.79% rise on Thursday, marking its 10th consecutive day of gains, driven by a 700% increase in preliminary revenues from Anktiva for the full year 2025 [1][3] Financial Performance - ImmunityBio reported $113 million in revenues from Anktiva, which is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer, indicating strong demand [2] - In the fourth quarter, ImmunityBio achieved $38.3 million in net revenues, reflecting a 431% increase compared to the same period last year [2] Sales Momentum - The company noted a quarter-over-quarter unit volume growth rate of 54% during FY 2025, indicating sustained sales momentum [3] - The approval from the Saudi Food and Drug Administration to market Anktiva in combination with an immune checkpoint inhibitor represents a strategic expansion opportunity for ImmunityBio in the Middle East [3][4]